Management depends on CTCAE grade and whether findings represent drug-induced ILD, radiation pneumonitis, infection, progression, or another cause.
-
Grade 1 ILD: hold T-DXd, consider corticosteroids, and reimage
Grade 1 ILD: immediate management Asymptomatic radiographic ILD/pneumonitis suspected during T-DXd treatment. Hold T-DXd until complete resolution to Grade 0. Evaluate alternative causes, including infection, tumor progression and radiation-related lung injury. Review chest imaging and consider pulmonology consultation. Consider systemic corticosteroids promptly (e.g., prednisolone ≥0.5 mg/kg/day or equivalent), based on clinical assessment. Monitoring Monitor for new cough, dyspnea, fever or oxygen desaturation. Arrange clinical and radiographic reassessment to document resolution before restarting T-DXd. Individualize the timing of follow-up imaging according to clinical findings. T-DXd restart criteria Resolution to Grade 0 within ≤28 days of onset: resume at the same dose. Resolution to Grade 0 after >28 days: resume at one dose level lower. For breast cancer, the first dose reduction is from 5.4 to 4.4 mg/kg. Stop rule If symptomatic drug-induced ILD/pneumonitis (Grade ≥2) develops, permanently discontinue T-DXd and promptly initiate systemic corticosteroid treatment.
-
Grade 1 ILD Recovered Promptly: Resume Same Dose
-
Resume at Reduced Dose: Use 5.4→4.4→3.2 mg/kg; Never Re-Escalate
These are the FDA-labeled breast cancer dose-reduction levels. Treatment should be discontinued if a further reduction is required, and doses must not be re-escalated.
-
Grade ≥2 Drug-Induced ILD: Permanently Discontinue T-DXd
This is a boxed-warning management requirement: permanently discontinue T-DXd and promptly initiate systemic corticosteroids for symptomatic Grade 2 or higher ILD.
-
Grade 2 Radiation Pneumonitis: Hold; Resume Same Dose After Resolution
In the adjuvant HER2-positive breast cancer setting, distinguish radiotherapy-related pneumonitis from T-DXd–induced ILD. Evaluation: Review symptoms, oxygenation, chest CT findings, radiation fields, timing of radiotherapy, and alternative causes, including infection. Suspected T-DXd–induced ILD: For Grade 1, interrupt T-DXd until complete resolution and follow the ILD dose-modification pathway. For Grade 2 or higher, permanently discontinue T-DXd and promptly initiate corticosteroids. Only radiotherapy-related pneumonitis suspected: For Grade 2, consider interrupting T-DXd. For Grade 3 or higher, permanently discontinue T-DXd. Reassess clinical recovery and diagnosis before considering treatment resumption. This radiotherapy-specific exception applies only in the adjuvant setting.
-
Grade ≥3 Radiation Pneumonitis: Permanently Discontinue T-DXd
-
Treat Alternative Cause; Continue T-DXd Once ILD Is Excluded